CVS lifts 2026 guidance after a sharp third-quarter rebound

By Amara Osei

CVS Health raised its full-year 2026 adjusted EPS guidance to at least $8.20 from the previous $7.90-$8.10 range after posting third-quarter adjusted EPS of $2.09, up 30.6% year over year and 29.01% above the Zacks Consensus Estimate.

Revenue rose 5.4% to $108.40 billion and beat consensus by 3.20%. Higher adjusted operating income in Health Care Benefits drove the improvement as CVS executed its margin-recovery plan. Shares climbed 1.9% in pre-market trading after the announcement.

What drove the segment results?

• Health Care Benefits revenue increased 2.4% to $36.86 billion. Growth in the Government business supported performance, partly offset by CVS's exit from the individual exchange business in 2026.
• Health Services revenue climbed 9.5% to $53.96 billion, driven primarily by pharmacy drug mix and brand inflation. Continued pharmacy client price improvements partly offset those gains.
• Pharmacy & Consumer Wellness revenue fell 2% to $35.50 billion. Regulatory-related price reductions, generic drug introductions and reimbursement pressure weighed on sales, while increased prescription volume, Rite Aid asset contributions and brand inflation provided partial offsets.

Pharmacy & Consumer Wellness also improved profitability, helped by core pharmacy strength and the Rite Aid asset contribution.

The mix favored insurance and pharmacy services, while the consumer business remained under pressure.

How did profitability change?

Gross profit, calculated as revenue less the cost of products sold and health care costs, rose 7.9% to $14.90 billion. Gross margin expanded approximately 30 basis points to 13.7%.

Operating income reached $3.57 billion, compared with an operating loss of $3.21 billion in the prior-year quarter. The change reflected higher adjusted operating income across all operating segments and the absence of a $5.73 billion goodwill impairment recorded a year earlier. Operating margin improved by approximately 640 basis points to 3.3% from negative 3.1%.

Adjusted operating income rose 21.2% to $4.19 billion. Adjusted operating margin expanded approximately 50 basis points to 3.9%, even as operating expenses edged up to $11.33 billion from $11.29 billion. Costs stayed nearly flat.

Profit recovered sharply without a material increase in operating expenses.

What did cash and debt show?

CVS ended the quarter with cash and cash equivalents of $11.74 billion, up from $8.45 billion at 2025-end. Long-term debt stood at $57.22 billion, down from $60.50 billion at the end of 2025.

Cumulative net cash provided by operating activities reached $15.32 billion, compared with $7.25 billion in the prior-year period. CVS also paid $2.58 billion in dividends during the first nine months of 2026 and repaid $4.06 billion of long-term debt.

Cash generation strengthened. Debt reduction and disciplined capital returns remain important watch items as the operating recovery advances.

What changed in the full-year 2026 outlook?

• Adjusted EPS guidance increased to at least $8.20 from $7.90-$8.10. The Zacks Consensus Estimate stands at $8.02.
• Revenue guidance increased to at least $420 billion from at least $414 billion, compared with consensus of $418.17 billion.
• Operating cash flow guidance rose to at least $15.50 billion from at least $11.50 billion.

The revision reflects improved expectations for Health Care Benefits and Pharmacy & Consumer Wellness. Management nevertheless maintained a cautious stance because medical-cost trends remained elevated and macroeconomic conditions could create further pressure.

Guidance moved higher. The new EPS and revenue floors exceed consensus, but management has not relaxed its cost warning.

Which operating developments matter beyond the numbers?

More than 69% of Aetna Medicare Advantage members are enrolled in 2027 plans rated four stars or higher. CVS also expanded its integrated GLP-1 weight-management offerings, while the Health100 mobile application received DirectTrust accreditation.

Medical-cost pressure, pharmacy reimbursement challenges and potential macroeconomic headwinds remain the principal risks.

The operating pipeline improved, though medical costs and reimbursement still dictate execution.

What did the cited medical-company results show?\n

Zacks classified CVS as Rank #3, labeled Hold, and cited three higher-ranked medical companies: Bausch + Lomb at #1, labeled Strong Buy; Medpace at #2, labeled Buy; and Intuitive Surgical at #2.

• Bausch + Lomb posted third-quarter adjusted EPS of 34 cents, exceeding consensus by 61.91%, and revenue of $1.28 billion, beating by 0.14%. Its estimated long-term earnings growth rate was 40.1%, versus 13.5% for the industry. It beat earnings estimates in three of the trailing four quarters, with a 21.67% average surprise.
• Medpace reported adjusted EPS of $4.84, 8.76% above consensus, and revenue of $716 million, 1.02% ahead. Its estimated long-term earnings growth rate was 14.3%, against industry growth of 13.2%. It beat estimates in each of the trailing four quarters, averaging a 9.77% surprise.
• Intuitive Surgical posted adjusted EPS of $3.00, exceeding consensus by 14.94%, and revenue of $3.05 billion, beating by 5.84%. Its earnings yield was 2.5%, compared with the industry's negative 2.1%. It beat estimates in all four trailing quarters, with a 15.12% average surprise.

CVS's raised guidance still depends on controlling medical costs and pharmacy reimbursement pressure.